Status:

COMPLETED

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

Lead Sponsor:

Azidus Brasil

Collaborating Sponsors:

Cellavita Pesquisa Científica Ltda

Hospital Vera Cruz

Conditions:

COVID-19 Pneumonia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.

Detailed Description

The number of infections of COVID-19 worldwide has killed thousands and is continually rising. The novel coronavirus attacks the human body by attaching to the angiotensin-converting enzyme-2 (ACE2), ...

Eligibility Criteria

Inclusion

  • 1\. Male or female, aged ≥ 18 years 2. Present a confirmed or pending diagnosis of COVID-19, but with tomographic and clinical signs strongly suggestive of SARS-CoV-2 infection (COVID-19), with pulmonary impairment greater than or equal to 50% and: i. Oxygen saturation \<95%; ii. CURB-65 rating ≥ a 4; d) Participants with a score on WHO ordinal scale that measures illness severity over time equal to 5 (Hospitalized with non-invasive ventilation or high-flow oxygen).

Exclusion

  • Patients with autoimmune diseases in the past or screening;
  • Those who have serious basic diseases that affect their survival, including: malignant tumor, hematopathy, malignant fluid, active hemorrhage, severe malnutrition, etc. which have not been controlled and can not be removed due to multiple metastasis;
  • Known or self-reported HIV or syphilis infected persons;
  • Have participated in stem cell clinical research;
  • Pregnant or lactating women or those who have fertility plans in the past year;
  • The estimated life cycle is less than 48 hours;
  • Other conditions that the researcher thinks are not suitable for participating in the experiment.
  • Shock
  • Continuous use of immunosuppressive agents or organ transplants in the past 6 months;

Key Trial Info

Start Date :

June 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 28 2021

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT04315987

Start Date

June 30 2020

End Date

February 28 2021

Last Update

October 28 2022

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Hospital Vera Cruz

Campinas, São Paulo, Brazil

2

Hospital de Barueri

São Paulo, Brazil

3

IncCOR

São Paulo, Brazil

4

UNIFESP

São Paulo, Brazil